UNASSIGNED:胶质瘤是一种无法治愈的恶性病变,预后不良,其特征是手术后有或没有放疗和化疗后容易复发。研究表明,COL6A2与多种肿瘤的发生发展密切相关。然而,COL6A2在胶质瘤中的作用以及COL6A2与肿瘤浸润免疫细胞之间的关系尚不清楚。
未经证实:Westernblot,实时PCR,应用组织微阵列和免疫组织化学技术检测胶质瘤中的COL6A2mRNA和蛋白含量,所有实验都重复三次。神经胶质瘤样品的组织微阵列用于预后分析。使用免疫组织化学方法检测COL6A2与免疫基因的共表达,和使用裸鼠进行肿瘤建模的预防和治疗研究。依据COL6A2mRNA的表达,将TCGA胶质瘤患者分为COL6A2低表达组和COL6A2高表达组,进行GO和KEGG通路分析。使用STRING构建了PPI网络,在CIBERSORT和TISIDB数据库中分析了COL6A2与肿瘤浸润免疫细胞和免疫基因的关联。胶质瘤中COL6A2mRNA和蛋白含量增加。
UNASSIGNED:多数据库和组织微阵列分析显示,COL6A2在神经胶质瘤中的表达与不良预后相关,组织微阵列显示,COL6A2在WHOIV中表达最高,在TCGA-GBM中的表达明显高于TCGA-LGG。免疫组织化学可以很好地证明COL6A2与免疫基因在裸鼠建立的肿瘤模型中的共表达。表明干扰COL6A2表达可能对肿瘤有抑制作用。COL6A2mRNA表达参与22条KEGG通路,和GSEA分析显示,28和57个基因集分别在标称p值<0.01和<0.05时显著富集,蛋白质网络揭示了COL6A2和SPARC之间的紧密相互作用。TheCIBERSORT数据库显示COL6A2与15种肿瘤浸润免疫细胞相关,包括M2巨噬细胞,CD8T细胞,中性粒细胞,γδT细胞,激活的CD4记忆T细胞,滤泡辅助性T细胞,M0巨噬细胞,M1巨噬细胞,调节性T细胞(Tregs),激活的NK细胞,嗜酸性粒细胞,激活的肥大细胞,单核细胞,激活的树突状细胞,和静息CD4记忆T细胞。TISIDB数据库显示COL6A2与调节性T细胞等淋巴细胞显著相关,17型辅助性T细胞,1型辅助T细胞,和免疫调节基因。此外,COL6A2相关的免疫调节基因显示,大多数免疫调节基因对胶质瘤具有预后价值,和高危免疫基因不利于胶质瘤患者的生存。
UNASSIGNED:COL6A2相关的免疫调节基因表明,大多数免疫调节基因对神经胶质瘤具有预后价值,和高危免疫基因不利于胶质瘤患者的生存。COL6A2可能是一种新的神经胶质瘤潜在的预后生物标志物,并与肿瘤微环境中的肿瘤浸润免疫细胞有关。干扰COL6A2表达可抑制肿瘤生长,这表明COL6A2是未来治疗的潜在目标。
UNASSIGNED: Glioma is an incurable malignant lesion with poor outcome characterized by easy recurrence after surgery with or without radiotherapy and chemotherapy. Studies have shown that
COL6A2 is closely related to the tumorigenesis and development of a variety of tumors. However, the role of
COL6A2 in glioma and the relationship between
COL6A2 and tumor infiltrating immune cells remain unclear.
UNASSIGNED: Western blot, real-time PCR, a tissue microarray and immunohistochemistry were applied to detect COL6A2 mRNA and protein amounts in glioma, and all experiments were repeated three times. A tissue microarray of glioma samples was used for prognostic analysis. Detection of COL6A2 co-expression with immune genes using immunohistochemical methods, and tumor modeling using nude mice for prevention and treatment studies. Based on the mRNA expression of COL6A2, patients with glioma in TCGA were divided into the low and high
COL6A2 expression groups, and GO and KEGG pathway analyses were performed. A PPI network was constructed using STRING, and the associations of COL6A2 with tumor-infiltrating immune cells and immune genes were analyzed in the CIBERSORT and TISIDB databases.
COL6A2 mRNA and protein amounts were increased in glioma.
UNASSIGNED: Multiple-database and tissue microarray analyses showed that COL6A2 expression in glioma was associated with poor prognosis, Tissue microarray showed that COL6A2 was the highest expressed in WHO IV and significantly higher in TCGA-GBM than in TCGA-LGG. Immunohistochemistry can well demonstrate the co-expression of COL6A2 with immune genes in a tumor model established in nude mice, showing that interference with COL6A2 expression may have an inhibitory effect on tumors. The mRNA expression of COL6A2 was involved in 22 KEGG pathways, and GSEA analysis showed that 28 and 57 gene sets were significantly enriched at nominal p values <0.01 and <0.05, respectively, protein network revealed a tight interaction between COL6A2 and SPARC. The CIBERSORT database indicated that COL6A2 was correlated with 15 types of tumor-infiltrating immune cells, including M2 macrophages, CD8 T cells, neutrophils, gamma delta T cells, activated CD4 memory T cells, follicular helper T cells, M0 macrophages, M1 macrophages, regulatory T cells (Tregs), activated NK cells, eosinophils, activated mast cells, monocytes, activated dendritic cells, and resting CD4 memory T cells. The TISIDB database indicated that COL6A2 was significantly correlated with lymphocytes such as regulatory T cell, Type 17 T helper cell, Type 1 T helper cell, and immunomodulatory genes. In addition, COL6A2-related immune regulatory genes show that most immune regulatorygenes have prognostic value for glioma, and high-risk immune genes are notconducive to the survival of glioma patients.
UNASSIGNED: COL6A2-related immune regulatory genes show that most immune regulatory genes have prognostic value for glioma, and high-risk immune genes are not conducive to the survival of glioma patients. COL6A2 may be a novel potential prognostic biomarker of glioma and associated with tumor-infiltrating immune cells in the tumor microenvironment, and interference with COL6A2 expression can inhibit tumor growth, which suggests
COL6A2 as a potential target for future treatment.